STOCK TITAN

Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Merck (NYSE: MRK) has scheduled its first-quarter 2025 sales and earnings conference call for Thursday, April 24, at 9:00 a.m. ET. The call will feature company executives presenting an overview of Merck's quarterly performance to institutional investors and analysts.

Participants can access the live audio webcast through a provided weblink, with a replay available later at www.merck.com along with the earnings release, supplemental financial disclosures, and results slides. Interested parties can also join via phone using the toll-free number (800) 369-3351 for U.S. and Canada, or (517) 308-9448, with access code 9818590.

Merck (NYSE: MRK) ha programmato la sua conferenza telefonica sui ricavi e sugli utili del primo trimestre 2025 per giovedì 24 aprile, alle 9:00 ET. Durante la chiamata, i dirigenti dell'azienda presenteranno una panoramica delle performance trimestrali di Merck agli investitori istituzionali e agli analisti.

I partecipanti possono accedere alla diretta audio tramite un link fornito, con una registrazione disponibile successivamente su www.merck.com insieme al comunicato sugli utili, ai documenti finanziari supplementari e alle diapositive dei risultati. Le parti interessate possono anche partecipare telefonicamente utilizzando il numero verde (800) 369-3351 per gli Stati Uniti e il Canada, oppure (517) 308-9448, con il codice di accesso 9818590.

Merck (NYSE: MRK) ha programado su conferencia telefónica sobre ventas y ganancias del primer trimestre de 2025 para el jueves 24 de abril a las 9:00 a.m. ET. La llamada contará con ejecutivos de la empresa que presentarán una visión general del desempeño trimestral de Merck a inversores institucionales y analistas.

Los participantes pueden acceder a la transmisión de audio en vivo a través de un enlace proporcionado, con una repetición disponible más tarde en www.merck.com junto con el comunicado de ganancias, divulgaciones financieras suplementarias y diapositivas de resultados. Las partes interesadas también pueden unirse por teléfono utilizando el número gratuito (800) 369-3351 para EE. UU. y Canadá, o (517) 308-9448, con el código de acceso 9818590.

머크 (NYSE: MRK)는 2025년 1분기 매출 및 수익 컨퍼런스 콜을 2024년 4월 24일 목요일 오전 9:00 ET로 예정하고 있습니다. 이 통화에서는 회사 경영진이 기관 투자자와 분석가에게 머크의 분기 실적 개요를 발표할 것입니다.

참가자는 제공된 링크를 통해 라이브 오디오 웹캐스트에 접속할 수 있으며, 이후 www.merck.com에서 수익 발표, 추가 재무 공시 및 결과 슬라이드와 함께 다시 들을 수 있습니다. 관심 있는 분들은 미국 및 캐나다를 위한 무료 전화번호 (800) 369-3351 또는 (517) 308-9448로 전화하여 접속 코드 9818590을 입력하여 참여할 수 있습니다.

Merck (NYSE: MRK) a programmé sa conférence téléphonique sur les ventes et les bénéfices du premier trimestre 2025 pour jeudi 24 avril à 9h00 ET. L'appel mettra en vedette des dirigeants de l'entreprise présentant un aperçu des performances trimestrielles de Merck aux investisseurs institutionnels et aux analystes.

Les participants peuvent accéder au webinaire audio en direct via un lien fourni, avec un replay disponible plus tard sur www.merck.com, ainsi que le communiqué de résultats, les divulgations financières supplémentaires et les diapositives de résultats. Les parties intéressées peuvent également se joindre par téléphone en utilisant le numéro sans frais (800) 369-3351 pour les États-Unis et le Canada, ou (517) 308-9448, avec le code d'accès 9818590.

Merck (NYSE: MRK) hat seine Telefonkonferenz zu Verkaufs- und Gewinnzahlen für das erste Quartal 2025 auf Donnerstag, den 24. April, um 9:00 Uhr ET angesetzt. Während des Anrufs werden Unternehmensleiter einen Überblick über die Quartalsleistung von Merck für institutionelle Investoren und Analysten präsentieren.

Teilnehmer können über einen bereitgestellten Link auf den Live-Audio-Webcast zugreifen, mit einer späteren Wiederholung unter www.merck.com, zusammen mit der Gewinnmitteilung, ergänzenden finanziellen Offenlegungen und Ergebnisfolien. Interessierte Parteien können auch telefonisch über die gebührenfreie Nummer (800) 369-3351 für die USA und Kanada oder (517) 308-9448 mit dem Zugangscode 9818590 teilnehmen.

Positive
  • None.
Negative
  • None.

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, April 24. During the call, company executives will provide an overview of Merck’s performance for the quarter.

Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com.

All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Free) or (517) 308-9448 and using the access code 9818590.

About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Media Contacts:

Robert Josephson

(203) 914-2372

robert.josephson@merck.com

Michael Levey

(215) 872-1462

michael.levey@merck.com

Investor Contacts:

Peter Dannenbaum

(732) 594-1579

Steven Graziano

(732) 594-1583

Source: Merck & Co., Inc.

FAQ

When is Merck (MRK) reporting Q1 2025 earnings?

Merck will report its Q1 2025 earnings on Thursday, April 24, 2025, at 9:00 a.m. ET.

How can investors access Merck's (MRK) Q1 2025 earnings call?

Investors can join via webcast through the provided weblink or by phone: (800) 369-3351 (US/Canada) or (517) 308-9448, using access code 9818590.

Where can I find Merck's (MRK) Q1 2025 earnings materials after the call?

Materials will be available at www.merck.com, including the webcast replay, earnings release, supplemental financial disclosures, and results slides.

What will be discussed in Merck's (MRK) Q1 2025 earnings call?

Company executives will provide an overview of Merck's performance for the first quarter of 2025.
Merck & Co

NYSE:MRK

MRK Rankings

MRK Latest News

MRK Stock Data

216.30B
2.52B
0.07%
80.45%
1.62%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
KENILWORTH